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Key Messages
1. To increase power, Mendelian randomization studies frequently combine study results (two-
stage meta-analysis) or study datasets (one-stage meta-analysis). When conducting a two-stage
meta-analysis, different variance estimators may not only impact coverage or type 1 error rates
but also point estimates.
2. In two-stage meta-analyses of weak instrument or rare diseases, resampling based variance
estimators are expected to result in biased point estimates with coverage below 0.95. Two-stage
meta-analyses using the delta-method are expected to perform better.
3. In the presence of between study heterogeneity, the delta-method applied at stage one of the
meta-analysis will likely result in the least biased estimate with relatively good coverage.
4. In one-stage meta-analysis scenarios, point estimates are not influenced by the choice of
variance estimator, and coverage is generally similar between the variance estimators. One-
stage meta-analyses are however, still affected by the size and quality of the included studies.
3Abstract
Background Mendelian randomization studies perform instrumental variable (IV) analysis using
genetic IVs. Results of individual Mendelian randomization studies can be pooled through meta-
analysis. We explored how different variance estimators influence the meta-analysed IV
estimate.
Method Two versions of the delta method (IV before or after pooling), four bootstrap estimators,
a jack-knife estimator and a heteroscedasticity-consistent (HC) variance estimator were
compared using simulation. Two types of meta-analyses were compared, a two-stage meta-
analysis, pooling results and a one-stage meta-analysis, pooling datasets.
Results Using a two-stage meta-analysis, coverage of the point estimate using bootstrapped
estimators deviated from nominal levels at weak instrument settings and/or outcome
probabilities ≤ 0.10. The jack-knife estimator was the least biased resampling method, the HC 
estimator often failed at outcome probabilities ≤ 0.50, and overall the delta method estimators 
were the least biased. In the presence of between study heterogeneity the delta method before
meta-analysis performed best. Using a one-stage meta-analysis all methods performed equally
well and better than two-stage meta-analysis of greater or equal size.
Conclusion In the presence of between study heterogeneity two-stage meta-analyses should
preferentially use the delta method before meta-analysis. Weak instrument bias can be reduced
by performing a one-stage meta-analysis.
Keywords Epidemiology methods; Mendelian Randomization Analysis; Statistics.
4Introduction
Despite considerable effort, observational (i.e., nonrandomized) studies are sensitive to
confounding bias and reverse causation(1-4). To overcome these problems, Mendelian
randomization (MR) studies have been advocated, using one or multiple Single-Nucleotide
Polymorphisms (SNPs) as an instrument in instrumental variable (IV) analyses(5;6).
In this type of Mendelian randomization study the effects of an IV on an intermediate phenotype
and on an outcome are estimated, and combined to derive the causal effect of the intermediate
on the outcome. This causal effect is unbiased if (amongst others) the following three
assumptions hold: [1] the IV is associated with phenotype, [2] conditional on the phenotype and
the (possibly unmeasured) confounders, the IV is independent of the outcome and [3] the IV is
independent of confounders(7).
While the performance of the different IV point estimators has previously been explored(8;9), the
performance of the different variance estimators remains unclear. This is especially important
because, to increase precision, Mendelian randomization studies often meta-analyse results
from multiple studies. Because of this, different variance estimators not only impact type-1 error
rates and confidence intervals but may also lead to different point estimates.
Typically three types of meta-analysis can be defined: an aggregated meta-analysis combining
study specific results; a two-stage individual patient data meta-analysis, in which an analysis
script is designed and shared prospectively, before pooling study specific results; and third, a
one-stage individual patient data meta-analysis sharing the actual datasets. Given the usually
straightforward analyses in genetic epidemiology the difference between aggregated meta-
analysis and two-stage individual patient data meta-analysis are often small, therefore here we
only differentiate between two-stage meta-analyses and one-stage meta-analyses. A recent
5review by Boef et.al.(10) showed that 47 out of 80 meta-analysis of Mendelian randomization
performed a two-staged analysis; among those, 10 performed IV analysis within each study
before combining, whereas 9 combined gene-phenotype and gene-outcome associations
separately before performing IV analysis. We note that gene scores are also used as
instruments(11), using aggregated results this can be implemented, for example, by meta-
analysing aggregated results of the gene-biomarker and the gene-outcome relationships into
two estimates(12) and applying the ratio estimator (see methods). Alternatively, when individual
patient data is available, gene scores can be implemented using the “two-stage least squared
like” estimator (TSLS, see methods).
In the present study we used simulations to compare multiple variance estimators. In addition,
an empirical example on the effect of low-density lipoprotein cholesterol (LDL-C) on
cardiovascular disease (CVD) is included.
Methods
Simulation set-up
Initially we focus on a two-stage meta-analysis where each study has information on a single
SNP (ܼ), a continuous phenotype (ܺ), and a dichotomous endpoint (ܻ). The goal is to estimate
the causal [marginal] odds ratio (OR) of one unit increase in phenotype on the outcome.
Data-generating process
J studies were simulated, for the ݆ݐℎ study a disease outcome, a phenotype and an IV were
generated for ௝݊ independent subjects, where ݆= 1, … ,ܬ. To increase readability the following
notation is presented for one study, with the same process applied to all studies. The IV
variable, ,ܼ counts the number of minor alleles for the ݅ݐℎ individual. Following a biallelic model,
6genotypes were generated from two independent Bernoulli distributions resulting in the usual
Hardy-Weinberg proportions:
ܲݎ݋ܾ (ܼ = 0,ܼ = 1,ܼ = 2) = (ݍଶ, 2݌ݍ,݌ଶ).
Where ݌ represents the probability of the rare allele and ݍ= 1 − ݌ the probability of the major
allele. Phenotype ܺ was generated dependent on ܼ and an unobserved confounder ܥ:
ݔ௜= ߙ଴ +ߙଵݖ௜+ ߙଶ ௜ܿ+ߝ௜ݓ ݅ݐℎߝ௜~ܰ (0,1), ௜ܿ~ܰ (0,1).
For the ݅ݐℎ individual the probability of an event was generated based on ܺ and ܥ:
݋݈݃ ݅ݐ(ܲݎ݋ܾ [ݕ௜= 1| ௜ܿ,ݔ௜]) = ݋݈݃ ൬ ܲݎ݋ܾ [ݕ௜= 1| ௜ܿ,ݔ௜]1 − ܲݎ݋ܾ [ݕ௜= 1| ௜ܿ,ݔ௜]൰= ߜ଴ + ߜଵ(ߙ଴ +ߙଵݖ௜+ ߙଶ ௜ܿ+ߝ௜) + ߜଶ ௜ܿ= ߜ଴ + ߜଵݔ௜+ ߜଶ ௜ܿ,
the event was sampled from a Bernoulli distribution:
ݕ௜~ܤ ݁݊ݎ ݋ݑ݈݈ (݅ܲݎ݋ܾ [ݕ௜= 1| ௜ܿ,ݔ௜]).
Data analyses
Point estimators
Given that the confounder ܥ is unobserved it is impossible to estimate the causal effect of the
phenotype ܺ on the outcome using regular methods such as logistic regression. Instead, SNP ܼ
can be used to estimate the causal effect of the phenotype on the outcome. The ratio estimator
7is a relatively straightforward estimator of the logarithm of the causal odds ratio (logOR), which is
the estimand here.
ߠ෠= (ߛොଵ− ߜመଷ)/ߙොଵ [1]
Here ߛොଵ represents the effect of the SNP on the outcome measured as the log(OR), ߜመଷ the
log(OR) effect of the SNP on the outcome conditional on the phenotype and unmeasured
confounders, and ߙොଵ the mean difference effect of the SNP on the phenotype (estimated by
fitting a linear regression of the type ݔ௜= ߙො଴ + ߙොଵݖ௜+ ߝ௜ [equation 2]). If every confounding
variable (C) was measured ߛොଵ and ߜመଷ, could be estimated by fitting the following (logistic
regression) models ݋݈݃ ݅ݐ(ܲݎ݋ܾ [ݕ௜= 1|ݖ௜]) = ߛො଴ + ߛොଵݖ௜and݈݋݃ ݅ݐ(ܲݎ݋ܾ [ݕ௜= 1|ݖ௜,ݔ௜, ௜ܿ]) = ߜመ଴ +
ߜመଵݔ௜+ ߜመଶ ௜ܿ+ ߜመଷݖ௜. However, because it is never known if all confounders are measured (and
correctly specified) this strategy is not feasible. Instead, following the exclusion restriction
(assumption 3 above), we assume that ߜመଷ = 0, and equation 1 reduces to the ratio of ߛොଵ and ߙොଷ.
This ratio estimator is typically used when there is a single instrument or when a multi gene
score is based on a meta-analysis of aggregated results(12).
Instead of the ratio estimator, the “two-stage least squares like” point estimator (TSLS), also
referred to as the two-stage predictor substitution estimators(13), is used to estimate the IV
effect using a (weighted) gene score (8).
݋݈݃ ݅ݐ(ܲݎ݋ܾ [ݕ௜= 1|ݔො௜]) = ߚመ଴ +ߠ෠ݔො௜ [3]
Where ݔො௜ represents the fitted value of a linear model regressing ݔ௜on ݖ௜ (i.e., the fitted values
from a linear regression defined in equation 2).
8Variance estimators
Following the usual research practice we will focus on a two-stage meta-analysis where in the
second stage study specific results are pooled by the inverse of the variance(14). Because
results are pooled by the inverse of the variance we initially focus on different variance
estimators, excluding methods that directly estimate a confidence interval.
The delta method(15;16) (DM) has the closed form solution:
ߪො஽ெ
ଶ = ఙෝംభమ(ఈෝభ)మ + ߪොఈభଶ (ఊෝభ)మ(ఈෝభ)ర− 2ߪොఊభ,ఈభଶ ఊෝభ(ఈෝభ)య [4]
Where ߪොఊభ
ଶ represents the estimated variance in ߛොଵ, ߪොఈభ
ଶ the variance in ߙොଵ and ߪොఊభ,ఈభଶ the
estimated covariance between ߛොଵ and ߙොଵ. Often the delta method is applied to meta-analysis
settings where ߪොఊభ,ఈభଶ is set to zero, resulting in a small over estimation of the variance; this was
followed here. Two versions of the delta method were compared: (1) calculating the ratio
estimator and the ߪො஽ெଶ in each study followed by meta-analysis of ߠ෠[DM1], and (2) calculating
ߠ෠using the ratio estimator and ߪො஽ெଶ after separately meta-analysing ߛොଵand ߙොଵ [DM2].
Alternatively, by sampling with replacement from the observed sample, creating a resampled
dataset of size ,݊ and repeating this ܤ times, a non-parametric bootstrapped distribution (17) can
be constructed. This distribution can then be used to estimate the variance in the IV point
estimate (basic bootstrap [BB]):
ߪො஻௢௢௧
ଶ = ଵ
஻ିଵ
∑ ൫̅ߠ∗ − ߠ෠௕
∗൯
ଶ஻
௕ୀଵ [5]
9With ߠ෠௕∗ the IV estimate estimated in the ܾݐℎ bootstrap sample and ̅ߠ∗ the mean IV estimate over
the ܤ bootstrap samples; here ܤ = 1,000.
All bootstrap variance estimators assume symmetry in bootstrap distribution, due to data
sparseness however, extreme values of ߠ෠∗ may occur, overestimation the ߪො஻௢௢௧ଶ . Straightforward
solutions that are less sensitive to data sparseness, include a bootstrap stratified for the
outcome [outcome stratified; OS] or stratified for the SNP status [SNP stratified; SS]. A more
computer intensive solution is to perform a double bootstrap [DB](17), where for every ܾݐℎ
bootstrap sample, ܴ new bootstrap samples of size ݊ are taken using the ܾݐℎ bootstrap sample
as the source population. For every ܾݐℎ bootstrap sample the variance is estimated, with the
median of these estimates representing the DB IV variance estimate. In our simulations ܴ= 50,
and ܤ஽஻ = ܴ ∗ 5. An jack-knife [JK](17) variance estimator can also be used:
ߪො௝௔௖௞
ଶ = ௡ି ଵ
௡
∑ ൫̅ߠ௝௔௖௞ − ߠ෠ି ௜൯
ଶ௡
௜ୀଵ
Here ̅ߠ௝௔௖௞ represents the mean IV estimate over the ݊ jack-knife estimates and ߠ෠ି ௜ the IV
estimate deleting the ݅ݐℎ observation.
The previous variance estimators were all applied using the ratio estimator. The robust
sandwich [RB] heteroscedasticity-consistent [HC] variance estimator can be used for the TSLS
IV, in which the variance estimate ߪො௫ො௬ଶ for ߠ෠(equation 3) is replaced by the RB estimate. Here we
used HC1 and note that JK and RB estimators are related in the sense that, the JK
approximates the HC3 estimator, which is a refinement of HC1(18). Note, that the HC estimators
are implemented not to adjust for any heteroscedasticity, but merely to penalize the naive
variance estimator which assumes that the ݔො in equation 3 is measured without error.
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Simulation scenarios
In all simulations ܬ= 10 studies were generated, with ௝݊ sampled from a uniform distribution
[400, 3600] (see Table 1 for an overview of the simulation parameters). In scenario I, the minor
allele frequency (݌) was set to 0.50, 0.10, 0.05, 0.01, and 0.005. The probability of the outcome
was 0.50. To (initially) prevent weak instrument bias (19) the SNP effect on the phenotype was
set to ߙଵ = 0.50, and the unmeasured confounder effect to ߙଶ = 0.50. By fixing the SNP-
phenotype association and decreasing ݌ the explained variance due to the SNP decreases, as
well as the F-statistic. For example, in scenario 1 the average F-statistic was 126, 46, 25, 6, and
5. To simulate a large amount of confounding the log(OR) of the unmeasured confounder effect
on the outcome was set to ߜଶ = 1.50, and the phenotype log(OR) set to ߜଵ = 0.00 (i.e., no causal
effect). In scenario II, ݌was set to 0.15 and the probability of the outcome was set to 0.10, 0.05,
0.02, and 0.01. Scenarios III and IV differed from II only with respect to ݌= {0.05, 0.01}.
All simulations were repeated 2,000 times and were performed with the statistical package R
version 3.1.2 for Unix(20). The number of replications was chosen to ensure sufficient precision
to detect small deviations from the nominal coverage rate of 0.95 (the 95% lower and upper
bounds are 0.940 and 0.960)(21). Results were pooled using the inverse variance method
following a fixed- or random-effects model where appropriate.
Performance metrics
Results were evaluated using the following metrics. Mean bias൫logORതതതതതതതത− log[ܶݎݑ ܱ݁ ܴ]൯, with the
first term representing the mean of the ݋݈݃ ܱ෢ܴ ; mean standard error [SE], empirical SE [ESE];
estimated by taking the standard deviation of the distribution of ݋݈݃ ܱ෢ܴ . The root mean squared
error ቈܴ ܯ ܵܧ = ට൫logORതതതതതതതത− log[ܶݎݑ ܱ݁ ܴ]൯ଶ + ܧ ܵܧଶ቉, coverage rate, defined as the proportion of
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times the 95% confidence interval included the true OR, and the number of models that failed to
return estimates.
Additional analyses
Obviously, the absolute performance of the methods depends on the mean sample size per
study. To explore the performance in a larger sample size setting, a “medium” sized meta-
analysis of 60,000 subjects was simulated by repeating scenario 1.
Instead of combining study results in a two-stage meta-analysis one can also combine datasets
in a one-stage meta-analysis. This was explored by repeating scenario 1, concatenating the
studies together in a single file and adjusting all analyses for study (i.e., bootstrapped by study
or adding a study covariable). Given that results do not have to be pooled in a second stage we
only report on a single DM estimator, and instead report on the bootstrap based percentile
confidence interval(22); which directly estimates the confidence interval (instead of the
variance).
In a third sensitivity analysis scenario 1 was repeated introducing between study variance of the
gene-phenotype association. This was simulated by replacing ߙ଴, ߙଵ, and ߝ௜by ߙ଴௝~ܰ(0.10, 1ଶ),
ߙଵ௝~ܰ(0.50, 1ଶ), and ߝ௜௝~ܰ(0, ௝߫ଶ) with ௝߫ଶ~ܰ(1.50, 0.3ଶ).
In a fourth sensitivity analysis we evaluated the performance of 1) using only the first term of the
delta method (the Toby Johnson [TJ] method), and 2) replacing the asymptotic variance
estimates, ߪොఊభ
ଶ , and ߪොఈభଶ , in the delta method (using the first two terms) by bootstrapped estimates
[DM BB]. Both methods were implemented by applying the algorithms before meta-analysis,
and after meta-analysis (i.e., TJ1, TJ2, DM1 BB, and DM2 BB). Performance was evaluated in
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scenario 1. Additionally, in a fifth sensitivity analysis, we explored performance for continuous
outcomes; implemented by repeating scenario 1 using the parameters of scenario 1 as mean
differences. See Appendix Figure 1 for a flowchart of the methods evaluated.
Results
Figure 1 depicts the performance of the IV variance estimators under different minor allele
frequencies (MAF) or instrument strengths (F-statistic). Unless explicitly stated all results pertain
to the two-stage meta-analysis. At a MAF of 0.50 pooled odds ratio (OR) estimates of all
methods were unbiased, but differences between the estimators increased as MAF decreased
to 0.005 (or F-statistic went towards zero). Coverage of both the DM estimators increased
towards 1.00 as MAF decreased; the RMSE was equal for both DM estimators, and smaller than
the RMSE of other methods (Figure 1). JK and RB coverage deteriorated towards 0.80 at lower
MAFs. Coverage of the bootstrap methods decreased below 0.95 at a MAF of 0.10/F-statistic
25, recovering to 0.95 at lower MAFs using the BB, SS and DB methods. This unexpected
behaviour in coverage was due to the bias in SE (i.e., difference between mean SE and ESE,
see Figure 1, Appendix table 1) trailing behind the bias in OR. Generally the mean SE and ESE
agreed well for the DM.
In scenarios II-IV the outcome incidence varied from 0.10 to 0.01 and the MAF was set to 0.15,
0.05, or 0.01 respectively (Appendix tables 2-4). At lower outcome probabilities bias in both DM1
and DM2 was similar, and lower than bias of other methods. For example, in scenario IV at an
outcome probability of 0.05 the mean OR was 1.339 and 1.572 for DM1 and DM2, respectively.
Coverage of DM1 and DM2 differed substantially at lower outcome probabilities, for example in
scenario IV with an outcome probability of 0.01 coverage was 0.793 and 0.550 respectively.
Differences between ESE and mean SE was similar however (DM1: -5.729, and DM2: -5.404),
as were the RMSE estimates (DM1: 3.268, and DM2: 3.670). Coverage of the JK and bootstrap
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methods was similar and decreased below 0.95 at lower outcome probabilities. RMSE was also
similar for all resampling methods, but higher than the DM methods. RB estimates were by far
the most biased, with the lowest coverage and highest RMSE; this coincided with frequent
failure of this method to return estimates.
Repeating scenario 1 with a larger sample size (60,000 subjects), showed a comparable relative
pattern as before (Figure 2, Appendix Table 5). Repeating scenario 1 using a one-stage meta-
analysis (20,000 subjects) improved performance. There was no difference between the
methods in, mean OR, bias, or RMSE (Appendix Table 6); even in extreme settings bias was
low -0.016 (MAF of 0.005 or F-statistic of 4). Coverage (Figure 3) was generally close to 0.95 or
slightly larger, and agreement between mean SE and ESE was generally good; only deviating at
a MAF of 0.005 or an F-statistic of 4. A non-parametric bootstrap percentile confidence interval
was evaluated, performing similar to other methods (coverage ≈ 0.95). Repeating scenario 1 
with between study variance showed similar performance as in the original fixed effect scenario
(Appendix Table 7), except for more conservative coverage rates, and DM2 being the most
biased estimator at MAF ≤ 0.01, e.g., -0.257 mean bias at MAF 0.005, which coincided with a 
coverage rate of almost 1, a RMSE of 10.289. DM1 performed better than all other methods with
a coverage of 0.981, and an RMSE of 0.127, at a MAF of 0.005.
The Toby Johnson [TJ] variance estimator performed comparably to the DM1 or DM2 in
scenario I with only slightly lower coverage (Appendix Table 8). Implementing the delta method
by replacing the asymptotic variance estimators with bootstrapped estimators [DM BB]
performed similarly to the BB method (Appendix Table 8). Repeating scenario 1 with a
continuous outcome revealed a comparable relative performance of the variance estimators
(Appendix Table 9).
14
Results on the LDL-C effect on CVD.
Table 2 shows empirical results of two different IV’s in a 6 study meta-analysis to estimate the
effect of LDL-C on CVD, (see Appendix for a description of the data sources, and baseline data).
Using SNP rs11591147 as an IV (mean F-statistic = 13.42) in a two-stage meta-analysis showed
that the bootstrap methods had the largest standard errors and their point estimates not only
disagreed with results from the remaining variance estimators but also between themselves. As
expected, using a one-stage meta-analysis increased precision and decreased differences
between methods, resulting in an IV estimate of 0.93 (95%CI 0.50;1.72). Results from the weak
instrument rs2965101 (mean F-statistic = 1.34) revealed large differences between the bootstrap
estimators and the remaining estimators; the minimal bootstrap SE estimate was 13.19,
compared to an SE of 1.49 using DM2. Precision increased using a one-stage meta-analysis,
however the bootstrapped SE were still comparatively large. Given that one-stage meta-analysis
are analysed by a single analyst, it becomes practical to explore the bootstrap distributions
(figure 4). After omitting a number of outliers the bootstrap became relatively symmetric and the
SE estimates were: 1.27 (BB), 1.29 (OS), 1.33 (SS), 3.51 (DB). The large SE of the DB and its
truncated distribution show that 50 times 250 repetitions were insufficient in this setting.
Discussion
This study showed that, depending on the strength of the IV and/or the outcome incidence, there
is considerable difference in the performance of instrumental variable (IV) variance estimators in
two-stage meta-analysis. The delta method (DM) showed the least amount of bias and the best
coverage; with the delta method implemented before meta-analysis performing better in the
presence of between study variance. Bootstrap and robust variance estimators (RB) produced
extreme estimates in two-stage meta-analysis. Differences between methods were minimal
using a one-stage meta-analysis; all providing unbiased estimates and appropriate coverage. An
empirical example on the LDL-C effect on CVD incidence, confirmed that these issues also
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occur in applied settings. Relative performance of the variance estimators was similar when
using a continuous outcome instead of a binary endpoint.
At lower MAF/F-statistic values, or lower outcome probabilities the RB estimators often failed to
converge, making it difficult to evaluate whether the underperformance of RB was due to the
estimator itself or to informative failures. Looking at the JK (which failed in less than 1% of the
simulations, and which is an approximation of the HC3 which is a refinement of the HC1 used in
the RB), it seems that to some extent this underperformance of the RB may be explained by
computational problems in the R sandwich package(23); this needs further study. Following the
usual practice in applied Mendelian randomization analyses, the ratio and the TSLS point
estimators were used. Additionally to the usual three IV assumptions, these point estimators also
assume the phenotype to be normally distributed conditional on the SNP and confounders, and
homogeneity of the phenotype (X) effect on the outcome (24). In our simulations these
assumptions held, however in applied settings this is not necessarily the case, given that
confounders are often unmeasured, these assumptions are also impossible to evaluate. Instead
of making these assumptions, different estimators or estimands may be considered in empirical
settings. For example, structural mean models or generalized method of moments point
estimators, or the risk difference estimand(8;24), make fewer assumptions.
Our results underline the difficulty of using the observed F-statistic(7) as a measure of expected
bias due to a weak instrument. We observed an increased performance in a one-stage meta-
analysis with on average 20,000 subjects and a “weak” instrument (MAF 0.05, mean F-statistic
5.97), compared to a two-stage meta-analysis with on average 60,000 subjects and a “strong”
instrument (MAF 0.05, mean F-statistic 15.98). When conducting a one-stage meta-analysis,
results do not have to be pooled by the inverse of an estimated study specific variance.
Therefore, in this scenario, point estimates, precision (ESE), and RMSEs were not influenced by
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the choice of variance estimators. The choice of variance estimator did influence coverage,
which was nevertheless markedly improved over a two-stage design.
The underperformance of the bootstrap estimators in the two-stage meta-analysis may come as
a surprise to some; however, the improved performance (over e.g., a Wald based confidence
interval) shown in the literature mostly holds for bootstrap confidence intervals such as the bias
corrected and accelerated bootstrapped confidence interval(17;22;25). Because of the need for
a variance estimate in the second stage of a two-stage meta-analysis the bootstrap can only be
used to estimate the standard error of the IV estimate, which implicitly assumes symmetry of the
bootstrap distribution(17;22;25). We did however evaluate the percentile method to directly
estimate the confidence interval when we replicated scenario 1 using a one-stage meta-
analysis. Results indeed showed proper coverage, however, this was similar to the increased
performance of all other estimators. We evaluated a delta method estimator replacing the
asymptotic variance estimates by bootstrapped variance estimates; this approach performed
worse than the regular delta method (DM1 or DM2). These results show that even though the
asymptotic approximations ofߪොఊభ
ଶ and ߪොఈభ
ଶ do not strictly hold these estimates are better
approximations (in such situations) than bootstrapped alternatives.
The simulations presented here are naturally limited and the following points merit discussion.
First, different simulation parameters will result in different absolute performance. Instead we
focussed on relative (i.e., between methods) performance which we expect to be more robust.
Second, by fixing the effect of the instrument (the SNP) on the phenotype, the instrument
strength decreases with MAF, hence our results include analyses with F-statistics below 10.
These are analyses, some might argue, an applied researcher would not perform due to
violation of IV assumption 1. We showed, however, that despite the “weak” instrument, valid
estimates can be derived. Third, while it seems logical to increase the number of bootstraps as
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the data becomes sparser (or the IV becomes weaker), we kept the number fixed to preserve
comparability between scenarios. Fourth, for simplicity we focussed on scenarios with a single
SNP instrument, whereas, to prevent weak-instrument bias, most Mendelian randomization
studies use multiple SNPs. Nevertheless, relevant information for these multiple SNP
approaches can be found in our analyses by focussing on strong-instrument settings. Fifth, we
only explored performance under the null [i.e., OR = 1] because, 1) coverage was often too low
making comparisons in power pointless, and 2) we wished to prevent influence of non-
collapsibility(26). Sixth, the small ORs observed in low frequency scenarios were most likely due
to the outcome being constant for a certain allele number (i.e., perfect separation). In these
settings penalized models, using for example a Firth(27;28) or Lasso(29) penalization, are
expected to perform better(30). Finally, random effects or fixed effect analysis models were used
depending on the simulation scenario including between study variance or not(31). In empirical
analyses, the choice between random effects and fixed effect models typically depends on a
heterogeneity measure(32). However, bias in point and variance estimates will influence the
observed heterogeneity, resulting in different modelling choices depending on the performance
of the estimator. This would make between methods comparisons difficult. Therefore, the choice
of model was based on the true, rather than the observed, between study variance.
In conclusion, the choice of variance estimator in instrumental variable analyses using a two-
stage meta-analysis is important. Simulations showed that the delta method applied at stage-
one of the two-stage meta-analysis performed best. If resampling variance estimators are used,
we suggest always checking study specific plots of these distributions for outliers. This is
especially important if the outcome and/or SNPs are rare or if the instrument is weak. Out of all
the resampling methods the jack-knife estimator performed best. However, in such a scenario an
even better alternative, when possible, is to perform a one-stage meta-analysis making the
choice of variance estimator less influential. If a one-stage design is used, resampling
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techniques can be used to directly estimate confidence intervals for which methods exist that do
not assume a symmetric distribution (e.g., the percentile method).
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Figure captions
Figure 1 Simulation results from scenarios I comparing different IV estimators.*
* solid line with a square symbol, delta method followed by meta-analysis [DM1]; solid line with a circle
symbol, basic bootstrap [BB]; solid line with triangle symbol, outcome stratified bootstrap [OS]; solid line
with a plus symbol, SNP stratified bootstrap [SS]; solid line with a filled out square symbol, double
bootstrap [DB]; solid line with a filled out circle symbol, jackknife estimator [JK]; solid line with a filled out
triangle symbol, robust variance estimator [RB]; solid line with a rhombus (diamond) symbol, meta-
analysis followed by delta method [DM2]. The DB y-value of 2.071 is not depicted for a MAF of 0.005 on
the bottom left graph.
Figure 2 Sensitivity analysis repeating simulation I comparing different IV estimators with an
average of 60,000 subjects.*
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* solid line with a square symbol, delta method followed by meta-analysis [DM1]; solid line with a circle
symbol, basic bootstrap [BB]; solid line with triangle symbol, outcome stratified bootstrap [OS]; solid line
with a plus symbol, SNP stratified bootstrap [SS]; solid line with a filled out square symbol, double
bootstrap [DB]; solid line with a filled out circle symbol, jackknife estimator [JK]; solid line with a filled out
triangle symbol, robust variance estimator [RB]; solid line with a rhombus (diamond) symbol, meta-
analysis followed by delta method [DM2].
Figure 3 Sensitivity analysis repeating simulation I comparing different IV estimators using a one
stage meta-analysis design with an average of 20,000 subjects.*
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* solid line with a square symbol, delta method followed by meta-analysis [DM1]; solid line with a circle
symbol, basic bootstrap [BB]; solid line with triangle symbol, outcome stratified bootstrap [OS]; solid line
with a plus symbol, SNP stratified bootstrap [SS]; solid line with a filled out square symbol, double
bootstrap [DB]; solid line with a filled out circle symbol, jackknife estimator [JK]; solid line with a filled out
triangle symbol, robust variance estimator [RB]; solid line with a star symbol, bootstrapped percentile
method. The BB y-value of -13.463 is not depicted for a MAF of 0.005 on the right graph.
Figure 4 Bootstrap distributions for IV rs2965101 for the relation of LDL-C and CVD.*
* Solid grey lines indicate the non-parametric density (only presented in the second row), with dashed
grey lines indicating the expected density given a normal distribution (not presented for the double
bootstrap).
27
Table 1 Simulation scenarios assessing performance of different variance estimators for an instrumental variance
analysis*.
Parameters Scenario I Scenario II Scenario III Scenario IV
Number of studies ܬ 10 10 10 10
Sample size sample from a uniform
distribution ܷ( ,ܽ )ܾ (400, 3600) (400, 3600) (400, 3600) (400, 3600)
Minor allele frequency ݌ {0.50, 0.10,
0.05,0.01,
0.005}
0.15 0.05 0.01
Effect of SNP on the phenotype ߙଵ 0.50 0.50 0.50 0.50
Effect of unobserved confounder on
the phenotype ߙଶ
1.00 1.00 1.00 1.00
Intercept ߙ଴ 0.10 0.10 0.10 0.10
Log(OR) of the phenotype effect on
the outcomeߜଵ
0.00 0.00 0.00 0.00
Log(OR) of the unobserved
confounder effect on the outcome
ߜଶ
1.50 1.50 1.50 1.50
Probability of the outcome 0.50 {0.10, 0.05,
0.02, 0.01}
{0.10, 0.05,
0.02, 0.01}
{0.10, 0.05,
0.02, 0.01}
Ln(odds) outcome intercept ߜ଴ 0.00 {-2.20, -2.94, -3.89, -4.60}
{-2.20, -2.94, -
3.89, -4.60}
{-2.20, -2.94, -
3.89, -4.60}
* Changes from the previous scenario (on the left) are presented in bold. Alpha’s represent mean differences, beta’s the natural
logarithm of the odds ratio.
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Table 2 Instrumental variable analysis of the LDL-C effect on CVD using instrument rs11591147 and rs2965101*.
Fixed effect 2 stage meta-
analysis
Random effects 2 stage
meta-analysis
Fixed effect 1 stage meta-
analysis
Heterogeneity statistics£
Odds ratio (95%CI) SE Odds ratio (95%CI) SE Odds ratio (95%CI) SE ˙Χ2(p-value) Τ2
Crude LDL-C association 1.06(1.01;1.11) 0.03 1.10(0.96;1.25) 0.07 1.06(1.01;1.11) 0.03 33.25(0.00) 0.02
rs11591147 IV LDL-C estimates
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]&
Percentile Method$
0.94(0.50;1.75)
1.24(0.48;3.18)
1.44(0.49;4.18)
0.89(0.30;2.64)
1.05(0.38;2.85)
0.90(0.45;1.81)
0.82(0.45;1.51)
0.87(0.46;1.65)
NA
0.32
0.48
0.55
0.55
0.51
0.35
0.31
0.33
NA
094(0.501.75)
1.24(0.48;3.18)
1.44(0.49;4.18)
0.89(0.30;2.64)
1.05(0.38;2.85)
0.90(0.45;1.81)
0.81(0.41;1.60)
0.85(0.40;1.80)
NA
0.32
0.48
0.55
0.55
0.51
0.35
0.35
0.38
0.00
0.93(0.50;1.72)
0.93(0.49;1.76)
0.93(0.49;1.78)
0.93(0.50;1.72)
0.93(0.50;1.72)
0.93(0.51;1.69)
0.93(0.50;1.74)
NA
0.93(0.49;1.78)
0.31
0.33
0.33
0.31
0.31
0.31
0.32
NA
NA
4.88(0.43)
0.98(0.98)
0.08(1.00)
0.38(1.00)
1.58(0.93)
4.05(0.58)
5.85(0.33)
7.47(0.19)/6.21 (0.29)
NA
0.00
0.00
0.00
0.00
0.00
0.00
0.11
0.01/0.03
NA
rs2965101 IV LDL-C estimates
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]&
Percentile Method$
1.55(0.35;17.90)
0.61(0.00;2*1021)
4.61(0.00;5*1030)
6.67(0.00;1029)
1.55(0.00;3*1011)
1.56(0.13;18.04)
3.03(0.47;19.47)
8.52(0.46;157.69)
NA
1.25
25.35
35.32
33.29
13.19
1.25
0.95
1.49
NA
1.55(0.13;17.90)
0.61(0.00;2*1021)
4.61(0.00;5*1030)
6.67(0.00;1029)
1.55(0.00;3*1011)
1.56(0.13;18.04)
2.72(0.20;37.48)
9.01(0.36;223.27)
NA
1.25
25.35
35.32
33.29
13.19
1.25
1.34
1.64
NA
8.16(0.50;132.64)
8.16(0.00;9*104)
8.16(0.00;6*107)
8.16(0.00;4*1015)
8.16(0.00;105)
8.16(0.70;95.04)
8.16(0.91;72.85)
NA
8.16(0.88;105)
1.42
4.77
8.07
17.21
4.93
1.25
1.12
NA
NA
3.11(0.66)
0.01(1.00)
0.01(1.00)
0.00(1.00)
0.03(1.00)
3.13(0.65)
8.11(0.13)
2.64(0.76)/6.14 (0.29)
NA
0.00
0.00
0.00
0.00
0.00
0.00
3.86
0.00/0.00
NA
* The mean F-statistics of two-stage designed IPDMAs were 13.42, and 1.34 for rs11591147 and rs2965101, respectively. The F-statistics of one-stage designed IPDMA were 500.07,
and 485.53 rs11591147 and rs2965101, respectively. The explained variance due to the instruments (measured as the squared spearman correlation coefficient) were 0. 70*10-2 and 0.
64*10-4. £ The heterogeneity statistics were determined for the fixed effect two-stage meta-analysis, tau-squared was calculated using the methods of moments estimator, chi-squared
test statistic and p-value were based on the Q-test. $ The percentile method is only available for the one-stage design. & For DM2 the heterogeneity statistics represent the
heterogeneity in ߛොଵ and ߛොଷ, see equation 2. DM = delta method; MA = meta-analysis; SE = standard error.
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Data sources for the empirical example of the LDL-C effect on CVD.
To empirically compare performance of the different estimators, see main text, we used SNP
rs11591147 in the PCSK9 gene and SNP rs2965101 in the BCL3 gene as instruments to
estimate the causal effect of LDL-C on CVD. Data were used from 6 studies in the UCLEB
consortium(1) (overall n = 11581 with minimal n = 764, and maximum n = 3041; overall CVD
events = 2050), British Regional Heat Study (BRHS)(2), Caerphilly Prospective Study
(CaPS)(3), Edinburgh Artery Study (EAS)(4), English Longitudinal Study of Ageing (ELSA)(5),
MRC National Survey of Health and Development (MRC46)(6), and Whitehall-II (WHII)(7).
Between study heterogeneity was measured using the Q-test (8) and the method of moments
estimator of the tau-squared (9). These two instruments were chosen because of a lack of
pleiotropy (Appendix 1 figure 1), small correlation (r < 0.01), their different frequency
(rs11591147 average ݌ = 0.02, min 0.02; max 0.02; rs2965101 average ݌ = 0.32, min 0.31; max
0.33), and different magnitudes of association with LDL-C (Spearman correlations of -0.082 and
-0.008 for rs11591147 and rs2965101 with LDL-C).
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Appendix table 1 Simulation results for scenario I assessing performance of different instrumental variable variance
estimators under different levels of MAF with an outcome probability of 0.50 *.
MAF = 0.500 MAF = 0.100 MAF = 0.050 MAF = 0.010 MAF = 0.005
Mean odds ratio (truth=1.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
1.778
1.004
1.012
1.012
1.012
1.011
1.011
1.004
1.000
1.826
1.010
1.033
1.033
1.033
1.031
1.029
1.009
0.998
1.840
1.015
1.060
1.060
1.061
1.054
1.046
1.012
0.991
1.851
1.089
1.229
1.234
1.222
1.212
1.180
1.104
0.993
1.853
1.142
1.528
1.506
1.474
1.620
1.331
1.400
0.973
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.576
0.004
0.012
0.012
0.012
0.011
0.011
0.004
0.000
0.602
0.010
0.033
0.033
0.033
0.031
0.028
0.009
-0.002
0.610
0.015
0.058
0.058
0.059
0.053
0.045
0.012
-0.009
0.616
0.085
0.206
0.211
0.201
0.193
0.166
0.099
-0.007
0.617
0.133
0.424
0.410
0.388
0.482
0.286
0.336
-0.027
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.959
0.951
0.950
0.951
0.952
0.948
0.954
0.958
0.000
0.967
0.946
0.944
0.943
0.949
0.939
0.958
0.963
0.000
0.958
0.926
0.925
0.915
0.934
0.922
0.944
0.950
0.000
0.978
0.959
0.957
0.930
0.965
0.904
0.943
0.978
0.000
0.982
0.956
0.952
0.942
0.946
0.887
0.815
0.986
Mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.012
0.040
0.041
0.041
0.041
0.041
0.040
0.040
0.040
0.012
0.068
0.071
0.071
0.070
0.071
0.067
0.067
0.068
0.013
0.093
0.104
0.104
0.101
0.104
0.093
0.092
0.094
0.013
0.202
0.472
0.479
0.389
0.400
0.201
0.191
0.212
0.013
0.281
1.445
1.466
1.106
1.072
0.288
0.256
0.347
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.012
0.040
0.040
0.040
0.040
0.040
0.040
0.040
0.040
0.012
0.063
0.064
0.064
0.064
0.064
0.063
0.065
0.066
0.013
0.089
0.094
0.094
0.094
0.093
0.091
0.094
0.096
0.013
0.159
0.252
0.248
0.244
0.237
0.164
0.306
0.204
0.013
0.205
1.196
1.639
1.278
3.143
0.522
0.995
0.372
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.576
0.040
0.041
0.041
0.041
0.041
0.041
0.040
0.040
0.602
0.063
0.072
0.072
0.072
0.071
0.069
0.065
0.066
0.610
0.091
0.110
0.111
0.111
0.107
0.102
0.095
0.097
0.616
0.180
0.325
0.325
0.316
0.305
0.233
0.322
0.205
0.617
0.245
1.269
1.689
1.336
3.179
0.595
1.050
0.373
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
12
12
12
15
12
ESE – mean SE
Crude
DM before MA [DM1]
0.000
-0.001
0.000
-0.005
0.000
-0.004
0.000
-0.044
0.000
-0.075
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
-0.001
-0.001
-0.001
-0.001
-0.001
0.000
0.000
-0.007
-0.007
-0.007
-0.008
-0.004
-0.002
-0.002
-0.010
-0.010
-0.007
-0.011
-0.002
0.003
0.003
-0.220
-0.231
-0.146
-0.163
-0.038
0.115
-0.008
-0.250
0.173
0.172
2.071
0.233
0.739
0.025
* MAF = minor allele frequency; DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard
error; ESE = empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of
the dichotomous outcome on the continuous phenotype. The mean F-statistics for the IV-phenotype association are: 126.42, 45.97,
24.67, 5.98, 3.47
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Appendix table 2 Simulation results for scenario II assessing performance of different instrumental variable variance
estimators under different probabilities for the outcome with the MAF fixed at 0.15. *
Prob(y = 1) = 0.1 Prob(y = 1) = 0.05 Prob(y = 1) = 0.02 Prob(y = 1) = 0.01
Mean odds ratio (truth=1.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
1.269
1.010
1.018
1.018
1.018
1.017
1.017
1.010
1.008
1.272
1.022
1.034
1.034
1.035
1.033
1.030
1.023
1.019
1.273
1.047
1.099
1.099
1.099
1.091
1.066
0.937
1.048
1.272
1.105
1.290
1.298
1.293
1.272
1.147
0.494
1.113
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.238
0.010
0.018
0.018
0.018
0.017
0.016
0.010
0.008
0.241
0.021
0.034
0.033
0.034
0.032
0.029
0.023
0.019
0.241
0.046
0.095
0.094
0.095
0.087
0.064
-0.065
0.047
0.240
0.100
0.254
0.261
0.257
0.241
0.137
-0.706
0.107
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.965
0.964
0.964
0.963
0.965
0.961
0.953
0.959
0.000
0.958
0.958
0.956
0.958
0.962
0.953
0.948
0.949
0.000
0.958
0.949
0.952
0.952
0.960
0.954
0.905
0.949
0.002
0.945
0.913
0.894
0.910
0.925
0.936
0.720
0.937
Mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.016
0.091
0.095
0.094
0.094
0.095
0.092
0.090
0.091
0.022
0.124
0.130
0.129
0.130
0.132
0.125
0.122
0.124
0.034
0.193
0.217
0.211
0.216
0.219
0.199
0.189
0.194
0.047
0.272
0.381
0.345
0.380
0.374
0.289
0.258
0.273
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.016
0.087
0.087
0.087
0.087
0.087
0.087
0.089
0.090
0.021
0.118
0.120
0.120
0.120
0.120
0.119
0.122
0.123
0.034
0.182
0.192
0.187
0.191
0.191
0.184
0.848
0.188
0.048
0.259
0.344
0.305
0.333
0.324
0.271
2.308
0.265
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.239
0.087
0.089
0.089
0.089
0.089
0.088
0.089
0.090
0.242
0.120
0.125
0.124
0.124
0.124
0.123
0.124
0.124
0.244
0.188
0.214
0.210
0.213
0.210
0.195
0.850
0.194
0.245
0.277
0.428
0.402
0.420
0.404
0.303
2.413
0.286
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
0
0
0
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0
ESE – mean SE
Crude
DM before MA [DM1]
0.000
-0.005
-0.001
-0.006
0.000
-0.011
0.001
-0.014
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
-0.007
-0.007
-0.007
-0.008
-0.005
-0.001
-0.002
-0.010
-0.010
-0.010
-0.011
-0.006
-0.001
-0.001
-0.024
-0.024
-0.025
-0.028
-0.015
0.659
-0.006
-0.037
-0.039
-0.047
-0.050
-0.019
2.050
-0.008
* MAF = minor allele frequency; DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard
error; ESE = empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of
the dichotomous outcome on the continuous phenotype. The mean F-statistic for the IV-phenotype association is 64.62.
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Appendix table 3 Simulation results for scenario III assessing performance of different instrumental variable variance
estimators under different probabilities for the outcome with the MAF fixed at 0.05. *
Prob(y = 1) = 0.10 Prob(y = 1) = 0.05 Prob(y = 1) = 0.02 Prob(y = 1) = 0.01
Mean odds ratio (truth=1.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
1.276
1.037
1.063
1.062
1.065
1.062
1.055
1.025
1.034
1.278
1.062
1.126
1.125
1.131
1.120
1.093
0.810
1.068
1.279
1.195
1.540
1.551
1.547
1.490
1.277
0.038
1.227
1.277
1.412
0.206
0.304
0.178
0.158
1.238
<0.001
1.490
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.244
0.036
0.061
0.060
0.063
0.060
0.054
0.024
0.033
0.245
0.060
0.119
0.118
0.123
0.114
0.089
-0.210
0.066
0.246
0.178
0.432
0.439
0.436
0.399
0.245
-3.272
0.205
0.244
0.345
-1.581
-1.191
-1.727
-1.846
0.213
-10.835
0.399
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.963
0.965
0.962
0.954
0.964
0.952
0.938
0.953
0.000
0.958
0.958
0.965
0.950
0.967
0.949
0.885
0.939
0.000
0.921
0.902
0.896
0.888
0.918
0.908
0.530
0.892
0.002
0.899
0.812
0.818
0.785
0.803
0.893
0.147
0.860
Mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.016
0.150
0.171
0.171
0.166
0.174
0.153
0.147
0.151
0.022
0.205
0.252
0.249
0.243
0.259
0.213
0.199
0.206
0.034
0.317
0.640
0.595
0.610
0.649
0.355
0.286
0.319
0.048
0.459
1.965
1.740
1.857
1.968
0.578
0.325
0.461
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.016
0.136
0.145
0.145
0.145
0.147
0.138
0.289
0.146
0.022
0.185
0.201
0.199
0.197
0.203
0.187
1.520
0.198
0.033
0.281
0.440
0.424
0.435
0.453
0.296
5.414
0.304
0.047
0.378
3.669
3.356
3.773
3.646
0.676
8.208
0.410
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.244
0.141
0.158
0.157
0.158
0.158
0.148
0.290
0.150
0.246
0.194
0.233
0.231
0.233
0.232
0.207
1.535
0.208
0.248
0.333
0.617
0.611
0.616
0.603
0.385
6.326
0.366
0.249
0.512
3.995
3.561
4.150
4.086
0.709
13.593
0.572
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
8
0
0
0
0
0
0
0
0
123
0
0
0
0
0
0
0
0
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0
ESE – mean SE
Crude
DM before MA [DM1]
-0.001
-0.014
0.000
-0.020
-0.001
-0.036
-0.001
-0.080
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
-0.026
-0.025
-0.021
-0.028
-0.014
0.142
-0.005
-0.051
-0.050
-0.046
-0.056
-0.027
1.321
-0.008
-0.200
-0.170
-0.175
-0.197
-0.059
5.128
-0.016
1.704
1.616
1.916
1.678
0.099
7.883
-0.051
* MAF = minor allele frequency; DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard
error; ESE = empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of
the dichotomous outcome on the continuous phenotype. The mean F-statistic for the IV-phenotype association is 24.66.
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Appendix table 4 Simulation results for scenario IV assessing performance of different instrumental variable variance
estimators under different probabilities for the outcome with the MAF fixed at 0.01. *
Prob(y = 1) = 0.10 Prob(y = 1) = 0.05 Prob(y = 1) = 0.02 Prob(y = 1) = 0.01
Mean odds ratio (truth=1.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
1.279
1.141
1.239
1.236
1.230
1.245
1.247
0.074
1.204
1.280
1.339
0.772
0.778
0.741
0.537
1.447
<0.001
1.572
1.284
2.181
0.013
0.014
0.011
0.008
0.171
<0.001
3.021
1.281
3.699
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
5.324
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.246
0.132
0.214
0.212
0.207
0.219
0.220
-2.605
0.186
0.247
0.292
-0.259
-0.251
-0.300
-0.622
0.370
-9.740
0.452
0.250
0.780
-4.324
-4.301
-4.502
-4.813
-1.765
-19.690
1.106
0.247
1.308
-9.525
-9.540
-10.020
-9.912
-9.437
-20.864
1.672
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.968
0.984
0.985
0.967
0.986
0.943
0.524
0.929
0.000
0.942
0.961
0.965
0.936
0.951
0.922
0.165
0.859
0.000
0.867
0.795
0.809
0.732
0.744
0.793
0.003
0.690
0.004
0.793
0.573
0.572
0.486
0.493
0.386
0.000
0.550
Mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.017
0.326
1.397
1.397
1.000
1.358
0.368
0.282
0.346
0.022
0.456
3.769
3.736
2.712
3.384
0.599
0.288
0.483
0.034
0.905
7.178
7.026
5.678
5.464
1.476
0.214
0.776
0.048
8.753
8.861
8.997
7.035
6.171
2.516
0.201
8.670
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.017
0.260
0.578
0.645
0.636
0.844
0.294
4.862
0.324
0.023
0.345
2.312
2.282
2.370
4.171
0.619
7.871
0.442
0.035
0.515
6.154
5.888
6.072
5.500
4.938
6.122
0.604
0.050
2.994
7.351
7.380
7.316
6.673
8.682
4.493
3.266
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.246
0.292
0.616
0.679
0.669
0.872
0.367
5.516
0.374
0.248
0.452
2.326
2.296
2.389
4.217
0.721
12.523
0.632
0.253
0.934
7.521
7.292
7.559
7.309
5.244
20.620
1.260
0.252
3.268
12.032
12.061
12.406
11.949
12.823
21.342
3.670
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
93
0
0
0
0
0
0
0
0
365
0
0
0
0
0
0
0
0
782
0
0
0
0
0
0
0
0
1305
0
ESE – mean SE
Crude
DM before MA [DM1]
0.000
-0.066
0.000
-0.111
0.000
-0.390
0.002
-5.759
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
-0.820
-0.752
-0.363
-0.514
-0.074
4.580
-0.022
-1.457
-1.454
-0.342
0.787
0.020
7.583
-0.041
-1.024
-1.138
0.394
0.036
3.462
5.909
-0.171
-1.510
-1.617
0.281
0.502
6.167
4.292
-5.404
* MAF = minor allele frequency; DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard
error; ESE = empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of
the dichotomous outcome on the continuous phenotype. The mean F-statistic for the IV-phenotype association is 5.95.
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Appendix table 5 Sensitivity analysis repeating simulation scenario 1 with an increased mean sample size of 60,000
subjects. *
MAF = 0.500 MAF = 0.100 MAF = 0.050 MAF = 0.010 MAF = 0.005
Mean odds ratio (truth=1.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
1.779
1.001
1.004
1.004
1.004
1.004
1.004
1.001
1.000
1.826
1.003
1.011
1.011
1.011
1.010
1.010
1.003
0.999
1.839
1.004
1.018
1.018
1.018
1.017
1.016
1.003
0.996
1.852
1.034
1.100
1.101
1.092
1.091
1.077
1.032
0.997
1.853
1.059
1.183
1.184
1.175
1.169
1.130
1.078
0.992
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.576
0.001
0.004
0.004
0.004
0.004
0.004
0.001
0.000
0.602
0.003
0.011
0.011
0.011
0.010
0.010
0.003
-0.001
0.609
0.004
0.017
0.017
0.018
0.017
0.016
0.003
-0.004
0.616
0.033
0.095
0.096
0.088
0.087
0.075
0.031
-0.003
0.617
0.057
0.168
0.169
0.161
0.157
0.122
0.075
-0.008
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.958
0.954
0.952
0.954
0.954
0.953
0.957
0.956
0.000
0.955
0.945
0.946
0.947
0.947
0.943
0.952
0.952
0.000
0.952
0.938
0.938
0.937
0.939
0.929
0.946
0.941
0.000
0.966
0.922
0.921
0.887
0.935
0.918
0.944
0.956
0.000
0.971
0.929
0.933
0.909
0.940
0.899
0.910
0.962
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.007
0.023
0.023
0.023
0.023
0.023
0.023
0.023
0.023
0.007
0.039
0.040
0.040
0.039
0.040
0.039
0.039
0.039
0.007
0.054
0.055
0.055
0.055
0.055
0.054
0.053
0.054
0.007
0.118
0.142
0.142
0.126
0.141
0.117
0.115
0.119
0.007
0.166
0.269
0.270
0.240
0.252
0.165
0.159
0.170
Empirical SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.007
0.023
0.023
0.023
0.023
0.023
0.023
0.023
0.023
0.007
0.038
0.038
0.038
0.038
0.038
0.038
0.039
0.039
0.007
0.053
0.054
0.054
0.054
0.054
0.054
0.054
0.055
0.007
0.104
0.117
0.118
0.119
0.114
0.106
0.139
0.118
0.007
0.137
0.222
0.229
0.235
0.273
0.149
0.274
0.167
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.576
0.023
0.023
0.023
0.023
0.023
0.023
0.023
0.023
0.602
0.038
0.040
0.040
0.040
0.040
0.039
0.039
0.039
0.609
0.053
0.057
0.057
0.057
0.057
0.056
0.054
0.055
0.616
0.109
0.151
0.153
0.148
0.144
0.130
0.143
0.118
0.617
0.149
0.278
0.284
0.285
0.315
0.193
0.284
0.167
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
4
4
4
4
4
4
7
4
ESE – mean SE
Crude
DM before MA [DM1]
0.000
-0.001
0.000
-0.001
0.000
-0.001
0.000
-0.014
0.000
-0.028
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
-0.001
-0.001
0.000
-0.001
0.000
0.000
0.000
-0.001
-0.001
-0.001
-0.001
-0.001
0.000
0.000
-0.001
-0.001
-0.001
-0.001
0.000
0.001
0.001
-0.025
-0.024
-0.007
-0.026
-0.011
0.024
-0.001
-0.047
-0.041
-0.004
0.021
-0.016
0.116
-0.003
* MAF = minor allele frequency; DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard
error; ESE = empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of
the dichotomous outcome on the continuous phenotype. The mean F-statistics for the IV-phenotype association are 375.98, 136.00,
72.20, 15.98, and 8.55.
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Appendix table 6 Sensitivity analysis repeating simulation scenario 1 with a mean sample size of 20,000 subjects using a
one stage meta-analysis design. *
MAF = 0.500 MAF = 0.100 MAF = 0.050 MAF = 0.010 MAF = 0.005
Mean odds ratio (truth=1.000)
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
1.780
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.827
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.840
0.997
0.997
0.997
0.997
0.997
0.997
0.997
0.997
1.853
0.991
0.991
0.991
0.991
0.991
0.991
0.991
0.991
1.855
0.984
0.984
0.984
0.984
0.984
0.984
0.984
0.984
Mean bias
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
0.576
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.603
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.610
-0.003
-0.003
-0.003
-0.003
-0.003
-0.003
-0.003
-0.003
0.617
-0.009
-0.009
-0.009
-0.009
-0.009
-0.009
-0.009
-0.009
0.618
-0.016
-0.016
-0.016
-0.016
-0.016
-0.016
-0.016
-0.016
Coverage
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
0.000
0.955
0.957
0.955
0.956
0.955
0.956
0.954
0.955
0.000
0.955
0.955
0.953
0.950
0.954
0.953
0.954
0.954
0.000
0.951
0.953
0.954
0.899
0.954
0.953
0.950
0.947
0.000
0.958
0.962
0.963
0.868
0.960
0.951
0.944
0.943
0.000
0.975
0.977
0.978
0.952
0.977
0.968
0.955
0.958
Mean SE
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
0.012
0.041
0.041
0.041
0.041
0.041
0.041
0.041
NA
0.012
0.068
0.068
0.068
0.067
0.068
0.068
0.068
NA
0.012
0.093
0.094
0.094
0.080
0.094
0.093
0.093
NA
0.013
0.211
0.227
0.227
0.174
0.224
0.213
0.209
NA
0.013
0.307
13.775
0.891
0.859
0.436
0.310
0.298
NA
ESE
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
0.012
0.040
0.040
0.040
0.040
0.040
0.040
0.040
0.040
0.013
0.067
0.067
0.067
0.067
0.067
0.067
0.067
0.067
0.013
0.094
0.094
0.094
0.094
0.094
0.094
0.094
0.094
0.013
0.218
0.218
0.218
0.218
0.218
0.218
0.218
0.218
0.013
0.312
0.312
0.312
0.312
0.312
0.312
0.312
0.312
RMSE
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
0.577
0.040
0.040
0.040
0.040
0.040
0.040
0.040
0.040
0.603
0.067
0.067
0.067
0.067
0.067
0.067
0.067
0.067
0.610
0.094
0.094
0.094
0.094
0.094
0.094
0.094
0.094
0.617
0.218
0.218
0.218
0.218
0.218
0.218
0.218
0.218
0.618
0.313
0.313
0.313
0.313
0.313
0.313
0.313
0.313
Number of failed models
Crude
Delta method [DM]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
ESE – mean SE
Crude
Delta method [DM]
0.000
-0.001
0.000
0.000
0.000
0.001
0.000
0.007
0.000
0.006
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
Percentile Method
-0.001
-0.001
-0.001
-0.001
-0.001
-0.001
-0.001
-0.001
-0.001
-0.001
0.000
-0.001
0.000
0.000
0.000
-0.001
0.000
0.000
0.014
0.000
0.001
0.001
0.001
0.000
-0.009
-0.009
0.044
-0.006
0.005
0.009
0.007
-0.009
-13.463
-0.578
-0.547
-0.124
0.002
0.014
0.006
-0.061
# The basic bootstrap percentile method does not estimate a standard error. * MAF = minor allele frequency; DM = delta method; MA
= meta-analysis; SNP = single nucleotide polymorphism ; SE = standard error; ESE = empirical standard error; RMSE = square root
of the mean squared error. The crude model regresses the log(odds) of the dichotomous outcome on the continuous phenotype. The
mean F-statistics for the IV-phenotype association 125.33, 45.95, 24.84, 5.93, and 3.55.
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Appendix table 7 Sensitivity analysis repeating simulation scenario 1 with between study variance, a mean sample size of
20,000 subjects, and using a two stage meta-analysis design. *
MAF = 0.500 MAF = 0.100 MAF = 0.050 MAF = 0.010# MAF = 0.005
Mean odds ratio (truth=1.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
1.375
1.001
1.003
1.002
0.905
1.025
1.004
1.002
0.978
1.418
1.002
1.006
1.006
1.006
1.016
1.007
1.002
0.996
1.437
1.006
1.012
1.012
1.011
1.005
1.014
1.006
0.996
1.453
1.019
1.007
1.035
1.023
1.044
1.042
1.021
15.21*109
1.454
1.033
1.050
1.140
1.069
1.020
1.066
1.041
0.773
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.318
0.001
0.003
0.002
-0.100
0.025
0.004
0.002
-0.023
0.349
0.002
0.006
0.006
0.006
0.016
0.006
0.002
-0.004
0.363
0.006
0.012
0.012
0.011
0.005
0.013
0.006
-0.004
0.374
0.019
0.007
0.035
0.022
0.043
0.041
0.021
23.445
0.374
0.033
0.049
0.131
0.067
0.019
0.064
0.040
-0.257
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.966
0.962
0.963
0.960
0.962
0.964
0.971
0.999
0.000
0.955
0.951
0.950
0.949
0.949
0.950
0.958
0.996
0.000
0.963
0.955
0.957
0.953
0.960
0.957
0.962
0.997
0.000
0.973
0.971
0.971
0.957
0.973
0.957
0.964
0.999
0.000
0.981
0.983
0.985
0.981
0.984
0.964
0.955
0.998
Mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.031
0.022
0.022
0.023
0.024
0.024
0.022
0.023
24.865
0.032
0.036
0.036
0.035
0.036
0.037
0.036
0.038
5.416
0.032
0.049
0.050
0.049
0.049
0.051
0.049
0.054
17.452
0.034
0.102
0.148
0.152
0.132
0.158
0.106
0.124
19.60*105
0.034
0.142
0.426
0.481
0.336
0.474
0.172
0.281
43.80*10
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.037
0.020
0.021
0.054
4.683
1.341
0.020
0.021
1.681
0.037
0.034
0.038
0.035
0.037
0.459
0.035
0.036
0.972
0.038
0.047
0.048
0.048
0.078
0.278
0.048
0.051
1.338
0.039
0.094
1.347
0.146
0.503
0.810
0.111
0.236
10.51*102
0.040
0.123
3.026
5.466
1.780
5.307
0.224
0.890
10.286
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.320
0.020
0.021
0.054
4.684
1.341
0.021
0.021
1.681
0.351
0.034
0.038
0.035
0.038
0.459
0.035
0.036
0.972
0.365
0.047
0.050
0.049
0.079
0.278
0.050
0.051
1.338
0.376
0.096
1.347
0.150
0.503
0.811
0.118
0.237
10.51*1010
0.377
0.127
3.027
5.467
1.782
5.307
0.233
0.891
10.289
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
5
5
5
5
5
5
28
5
ESE – mean SE
Crude
DM before MA [DM1]
0.005
-0.002
0.006
-0.001
0.006
-0.002
0.005
-0.008
0.007
-0.019
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Basic bootstrap [BB]
Outcome stratified bootstrap [OS]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
-0.001
0.031
4.659
1.316
-0.002
-0.002
-23.184
0.002
-0.001
0.001
0.422
-0.001
-0.002
-4.444
-0.002
-0.002
0.029
0.227
-0.001
-0.003
-16.113
1.199
-0.006
0.371
0.652
0.005
0.112
-195.978*104
2.600
4.985
1.444
4.833
0.052
0.609
-427.721
# The large deviation of the DM2 method seen at a MAF of 0.010 is due to an single estimated log odds ratio of 46988.78, excluding
this value results in a mean OR, mean bias, and empirical SE of 0.952, -0.049, 29.869 respectively. * MAF = minor allele frequency;
DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard error; ESE = empirical standard
error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of the dichotomous outcome on the
continuous phenotype. The mean F-statistics for the IV-phenotype association are 408.31, 147.15, 77.54, 17.16, 9.02.
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Appendix table 8 Sensitivity analysis repeating simulation scenario 1 with additional variance estimators. *
MAF = 0.500 MAF = 0.100 MAF = 0.050 MAF = 0.010# MAF = 0.005
Mean odds ratio (truth=1.000)
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
1.778
1.003
0.999
1.002
0.999
1.825
1.010
0.998
1.009
0.998
1.839
1.018
0.998
1.013
0.998
1.850
1.066
0.978
1.106
0.976
1.854
1.126
0.966
1.238
1.177
Mean bias
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0.576
0.003
-0.001
0.002
-0.001
0.602
0.010
-0.002
0.009
-0.002
0.609
0.018
-0.002
0.013
-0.002
0.615
0.064
-0.022
0.101
-0.024
0.617
0.119
-0.035
0.213
0.163
Coverage
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0.000
0.950
0.949
0.954
0.947
0.000
0.960
0.957
0.966
0.961
0.000
0.949
0.949
0.962
0.953
0.000
0.942
0.946
0.969
0.952
0.000
0.940
0.967
0.889
0.859
Mean SE
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0.012
0.040
0.041
0.041
0.041
0.012
0.067
0.067
0.105
0.068
0.012
0.091
0.093
0.151
0.094
0.013
0.192
0.210
238.758
0.228
0.013
0.261
0.313
28.277
0.757
ESE
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0.012
0.040
0.040
0.040
0.040
0.013
0.065
0.067
0.085
0.067
0.013
0.092
0.094
0.108
0.094
0.012
0.190
0.215
3.274
0.297
0.013
0.243
0.311
2.183
4.730
RMSE
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0.576
0.040
0.040
0.041
0.040
0.602
0.066
0.067
0.086
0.067
0.610
0.093
0.094
0.108
0.094
0.616
0.201
0.216
3.275
0.298
0.617
0.270
0.313
2.193
4.733
Number of failed models
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
22
22
22
ESE – mean SE
Crude
TJ before MA [DM2]
TJ after MA [TJ2]
DM with BB before MA [DM1 BB]
DM with BB after MA [DM2 BB]
0.000
0.000
0.000
-0.001
0.000
0.000
-0.001
-0.001
-0.020
-0.001
0.000
0.000
0.000
-0.043
0.000
0.000
-0.002
0.005
-235.485
0.069
0.000
-0.018
-0.001
-26.094
3.973
* MAF = minor allele frequency; TJ = Toby Johnson; MA = meta-analysis; BB = basic bootstrap; SE = standard error; ESE =
empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of the
dichotomous outcome on the continuous phenotype. The mean F-statistics for the IV-phenotype association are 125.45, 46.14,
24.76, 5.99, 3.45.
45
Appendix table 9 Sensitivity analysis repeating simulation scenario 1 with using a continuous outcome. *
MAF = 0.500 MAF = 0.100 MAF = 0.050 MAF = 0.010 MAF = 0.005
Mean, mean difference (truth=0.000)
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.706
0.005
0.016
0.016
0.016
0.015
0.005
-0.001
0.741
0.031
0.090
0.091
0.086
0.074
0.027
-0.002
0.749
0.191
0.386
0.382
0.341
0.342
0.223
-0.033
0.748
0.113
0.277
0.265
0.266
0.224
0.108
-0.021
0.749
0.191
0.386
0.382
0.341
0.342
0.223
-0.033
Mean bias
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.706
0.005
0.016
0.016
0.016
0.015
0.005
-0.001
0.734
0.014
0.046
0.046
0.044
0.040
0.013
-0.003
0.741
0.031
0.090
0.091
0.086
0.074
0.027
-0.002
0.748
0.113
0.277
0.265
0.266
0.224
0.108
-0.021
0.749
0.191
0.386
0.382
0.341
0.342
0.223
-0.033
Coverage
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.949
0.921
0.923
0.922
0.921
0.946
0.952
0.000
0.953
0.885
0.878
0.885
0.884
0.944
0.947
0.000
0.947
0.831
0.816
0.836
0.836
0.932
0.956
0.000
0.943
0.820
0.778
0.807
0.684
0.873
0.958
0.000
0.923
0.834
0.776
0.759
0.602
0.728
0.974
Mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.007
0.036
0.037
0.037
0.037
0.036
0.036
0.036
0.007
0.061
0.063
0.063
0.063
0.060
0.060
0.061
0.007
0.083
0.091
0.089
0.090
0.081
0.081
0.084
0.007
0.181
0.392
0.325
0.306
0.164
0.164
0.190
0.007
0.246
0.934
0.743
0.530
0.212
0.200
0.281
ESE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.007
0.036
0.037
0.037
0.037
0.037
0.037
0.037
0.007
0.058
0.060
0.060
0.060
0.059
0.060
0.061
0.007
0.075
0.082
0.082
0.081
0.079
0.080
0.083
0.007
0.140
0.220
0.219
0.199
0.151
0.167
0.194
0.007
0.180
0.420
0.496
2.100
0.240
0.322
0.300
RMSE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.706
0.037
0.040
0.040
0.040
0.040
0.037
0.037
0.734
0.060
0.075
0.075
0.074
0.071
0.061
0.061
0.741
0.081
0.122
0.123
0.118
0.108
0.085
0.083
0.748
0.180
0.354
0.344
0.333
0.270
0.199
0.195
0.749
0.263
0.570
0.627
2.127
0.418
0.392
0.302
Number of failed models
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
12
12
12
12
12
12
ESE – mean SE
Crude
DM before MA [DM1]
Basic bootstrap [BB]
SNP stratified bootstrap [SS]
Double bootstrap [DB]
Jackknife [JK]
Robust HC1 [RB]
DM after MA [DM2]
0.000
0.000
0.000
0.000
0.000
0.001
0.001
0.001
0.000
-0.003
-0.004
-0.003
-0.003
-0.001
0.000
0.001
0.000
-0.008
-0.009
-0.006
-0.009
-0.002
-0.001
0.000
0.000
-0.041
-0.172
-0.106
-0.107
-0.014
0.004
0.004
0.000
-0.066
-0.514
-0.246
1.570
0.027
0.121
0.019
* MAF = minor allele frequency; DM = delta method; MA = meta-analysis; SNP = single nucleotide polymorphism ; SE = standard
error; ESE = empirical standard error; RMSE = square root of the mean squared error. The crude model regresses the log(odds) of
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the dichotomous outcome on the continuous phenotype. The mean F-statistics for the IV-phenotype association are: 125.63, 46.04,
24.93, 5.94, 3.49
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Appendix table 10 Baseline characteristics of a 6 study IPDMA using SNPs rs11591147 and rs2965101 in an instrumental
variables analysis of the LDL-C effect on CVD*.
BRHS CaPS EAS ELSA
Mean(sd) n Mean(sd) n Mean(sd) n Mean(sd) n
CVD 0.34 802 0.17 182 0.67 510 0.86 1624
Men 1.00 2342 1.00 1087 0.48 370 0.53 993
Age (years) 68.91(5.62) 2342 56.77(4.46) 1065 64.51(5.64) 764 73.69(9.44) 1883
Systolic blood pressure (mm Hg) 144.17(19.95) 2340 145.78(22.40) 1061 143.42(23.76) 763 139.01(19.66) 1662
Diastolic blood pressure (mm Hg) 81.88(12.86) 2340 84.56(12.01) 1061 77.46(12.20) 761 72.97(11.43) 1662
Cholesterol (mmol/L) 6.37(1.04) 2331 5.63(1.00) 1031 7.11(1.34) 763 5.71(1.28) 1873
HDL-C (mmol/L) 1.15(0.25) 2245 1.03(0.25) 1031 1.45(0.37) 760 1.49(0.39) 1872
LDL-C (mmol/L) 3.89(1.00) 2277 3.75(0.90) 1006 5.35(1.24) 760 3.43(1.06) 1835
Triglycerides (mmol/L) 2.06(1.23) 1500 1.92(1.14) 1031 1.53(0.87) 763 1.80(1.11) 1873
rs11591147 (n rare alleles)
0
1
2
0.97
0.03
0.00
2261
81
0
0.97
0.03
0.00
1050
37
0
0.97
0.11
0.00
739
81
0
0.97
0.06
0.00
1819
121
0
rs2965101 (n rare alleles)
0
1
2
0.46
0.44
0.10
1073
1023
245
0.46
0.44
0.10
498
477
112
0.46
0.44
0.03
351
334
25
0.48
0.42
0.03
906
795
64
Total sample size 2342 1087 764 1883
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Appendix table 10 continued.
MRC46 WHII Total
Mean(sd) n Mean(sd) n Mean(sd) n
CVD 0.06 144 0.14 409 0.18 2624
Men 0.50 1231 0.23 713 0.56 8422
Age (years) 53.00(0.00) 2464 48.94(5.98) 3041 59.63(11.21) 11559
Systolic blood pressure (mm Hg) 136.22(20.01) 2425 120.37(13.01) 3034 135.40(21.20) 11285
Diastolic blood pressure (mm Hg) 84.55(12.17) 2425 79.63(9.11) 3034 80.49(12.08) 11283
Cholesterol (mmol/L) 6.09(1.07) 2314 6.44(1.13) 3040 6.21(1.20) 11352
HDL-C (mmol/L) 1.67(0.52) 2149 1.41(0.40) 3023 1.39(0.44) 11087
LDL-C (mmol/L) 3.52(0.97) 2139 4.37(1.01) 2980 3.96(1.14) 11004
Triglycerides (mmol/L) 2.16(1.51) 2310 1.44(1.15) 3041 1.80(1.26) 10517
rs11591147 (n rare alleles)
0
1
2
0.96
0.04
0.00
2368
94
2
0.97
0.03
0.00
2947
92
2
0.97
0.03
0.00
11184
393
4
rs11206510 (n rare alleles)
0
1
2
0.47
0.44
0.10
1154
1074
236
0.45
0.45
0.10
1362
1373
306
0.46
0.44
0.10
5327
5093
1160
Total sample size 2464 3041 11581
* The baseline numbers are based on complete data on CVD, and SNPS.
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Appendix figure 1 Flowchart of the implementation of the different variance estimators in a simulation study of a two-stage
meta-analysis of an instrumental variable analysis*.
*MA; meta-analysis, SS; SNP stratified, OS; outcome stratified.
50
Appendix Figure 2 Spearman pairwise correlation matrix for PCSK9 SNPs rs13465, rs6511720, and multiple phenotypes;
with p-values for non-significant associations depicted (alpha = 0.05).
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